Intermediate dose of g-csf and mobilization of blood stem cells in 7 healthy donors

Faster engraftment with decreased neutropenia and Increased graft-versus-leukemia are generally observed in bone marrow transplantation with peripheral blood stem cells (PBSC), moreover PBSC transplantation following cytokine mobilization avoids the risk of anaesthesia and the discomfort associated to bone marrow harvesting in the donor. However G-CSF followed by several leukaphereses may lead to not well known side effects, while the optimal schedule to collect blood SC in healthy donors remain to be defined. With the aim of evaluating the possibility of reducing the duration of G-CSF administration here we report the growth of progenitor hematopoietic cells and the absolute number of CD34+ cells analysed after every day of G-CSF therapy in 7 healthy donors. They received G-CSF 5ug/Kg/day subcutaneously for 5 days. The leukaphereses were performed in the morning of the 5th day.). The results are reported in tab.1 tab.1. Hematopoietic progenitor growth and CD34+ cells expressed as mean ±Standard Deviation (SO) In 7 health donors treated with G-CSF. CFU-GM BFU-E CFU-GEMM CD 34+ ×10⁵ cells ×10⁵ cells ×10⁵ cells /pi day 0 21±2 13±3 1+1 1 35±7 35+20 1.9±2 10.6+11 2 61±15 59±28 2.8±2 12.6+8 3 46±13 91±31 6±3 39.6±31 4 130±24 130±59 16±10 97.17±40 5 114±50 128±27 8±2 108±60 leukaphereses 147±49 183±66 15±10 G-CSF gives an increase of the progenitor and CD34+ cell number after every day of therapy. The highest levels of CD34+ cells and CFU-GM were counted after 4-5 days of G-CSF administration, but high level of the hemopoietic progenitors are observed still in 3rd day of G-CSF therapy. These data are suggestive of the possibility of reducing the course of this kind of treatment. This fact may have an impact on the duration of G-CSF therapy in healthy subjects.